WO2008093650A1 - ピペラシリンナトリウムの新規な結晶 - Google Patents

ピペラシリンナトリウムの新規な結晶 Download PDF

Info

Publication number
WO2008093650A1
WO2008093650A1 PCT/JP2008/051232 JP2008051232W WO2008093650A1 WO 2008093650 A1 WO2008093650 A1 WO 2008093650A1 JP 2008051232 W JP2008051232 W JP 2008051232W WO 2008093650 A1 WO2008093650 A1 WO 2008093650A1
Authority
WO
WIPO (PCT)
Prior art keywords
novel crystal
piperacillin sodium
crystals
diffraction angles
piperacillin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/051232
Other languages
English (en)
French (fr)
Inventor
Masaru Mouri
Dai Nishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008556092A priority Critical patent/JP5173842B2/ja
Priority to EP08704041A priority patent/EP2128162A4/en
Priority to BRPI0808375-4A priority patent/BRPI0808375A2/pt
Priority to CA002676803A priority patent/CA2676803A1/en
Priority to AU2008210929A priority patent/AU2008210929A1/en
Priority to MX2009008124A priority patent/MX2009008124A/es
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Priority to US12/524,875 priority patent/US20100063273A1/en
Priority to KR1020097016429A priority patent/KR20090104855A/ko
Publication of WO2008093650A1 publication Critical patent/WO2008093650A1/ja
Priority to IL200087A priority patent/IL200087A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
    • C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
    • C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
    • C07D499/68—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms with aromatic rings as additional substituents on the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

　粉末Ｘ線回折において、２θで表される３．７、５．５、７．３、１１．６、１４．５及び１８．０°の回折角度を有するピペラシリンナトリウムの新規な結晶並びに５．６、７．８、１２．３、１５．５、１７．５、２３．３、２４．８及び２８．５°の回折角度を有するピペラシリンナトリウムの新規な結晶は、優れた安定性、溶解性及び低吸湿性を有し、原薬の製造時及び製剤化での充填時の取り扱いが非常に容易であり、それらを充填した注射用製剤は、有用である。
PCT/JP2008/051232 2007-01-31 2008-01-29 ピペラシリンナトリウムの新規な結晶 Ceased WO2008093650A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP08704041A EP2128162A4 (en) 2007-01-31 2008-01-29 NEW SODIUM PIPERACILLIN CRYSTAL
BRPI0808375-4A BRPI0808375A2 (pt) 2007-01-31 2008-01-29 Composto
CA002676803A CA2676803A1 (en) 2007-01-31 2008-01-29 Novel crystal of piperacillin sodium
AU2008210929A AU2008210929A1 (en) 2007-01-31 2008-01-29 Novel crystal of piperacillin sodium
MX2009008124A MX2009008124A (es) 2007-01-31 2008-01-29 Cristal nuevo de piperacilina sodica.
JP2008556092A JP5173842B2 (ja) 2007-01-31 2008-01-29 ピペラシリンナトリウムの新規な結晶
US12/524,875 US20100063273A1 (en) 2007-01-31 2008-01-29 Novel crystal of piperacillin sodium
KR1020097016429A KR20090104855A (ko) 2007-01-31 2008-01-29 피페라실린나트륨의 신규 결정
IL200087A IL200087A0 (en) 2007-01-31 2009-07-27 Novel crystal of piperacillin sodium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007020758 2007-01-31
JP2007-020758 2007-01-31

Publications (1)

Publication Number Publication Date
WO2008093650A1 true WO2008093650A1 (ja) 2008-08-07

Family

ID=39673961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051232 Ceased WO2008093650A1 (ja) 2007-01-31 2008-01-29 ピペラシリンナトリウムの新規な結晶

Country Status (12)

Country Link
US (1) US20100063273A1 (ja)
EP (1) EP2128162A4 (ja)
JP (1) JP5173842B2 (ja)
KR (1) KR20090104855A (ja)
CN (1) CN101611040A (ja)
AU (1) AU2008210929A1 (ja)
BR (1) BRPI0808375A2 (ja)
CA (1) CA2676803A1 (ja)
IL (1) IL200087A0 (ja)
MX (1) MX2009008124A (ja)
RU (1) RU2009132516A (ja)
WO (1) WO2008093650A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011040386A1 (ja) * 2009-09-30 2011-04-07 富山化学工業株式会社 ピペラシリンナトリウム・１水和物の新規な結晶
JP2015531778A (ja) * 2012-09-14 2015-11-05 ベイジン シンティエンユー テクノロジー ディベロップメント シーオー エルティーディー ピペラシリンナトリウムとスルバクタムナトリウムの共晶及びその製造方法、並びに当該共晶を含む医薬組成物及びその応用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102977119A (zh) * 2012-12-14 2013-03-20 江西富祥药业股份有限公司 一种用溶媒法制备哌拉西林钠的工艺
CN109134497A (zh) * 2017-07-24 2019-01-04 陈立平 一种1/2水哌拉西林钠化合物
CN109160918A (zh) * 2017-07-27 2019-01-08 海南美兰史克制药有限公司 一种1/4水哌拉西林钠化合物及其药物组合物制剂
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5123284A (en) 1974-08-13 1976-02-24 Toyama Chemical Co Ltd Shinkina penishirinruino seizoho
JPH0232082A (ja) 1988-07-21 1990-02-01 Maruko Seiyaku Kk ペニシリン誘導体の製造方法
US20030028016A1 (en) 2001-08-03 2003-02-06 Alberto Brandt Process for the preparation of the sodium salt of 6[D-(-)alpha-4-(ethyl-2,3-dioxo-1-piperazinocarbonylamino) phenylacetamido]penicillanic acid
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
JP2007246514A (ja) * 2006-02-14 2007-09-27 Toyama Chem Co Ltd ピペラシリンナトリウムの新規な結晶

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) * 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4379152A (en) * 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
DE2732104A1 (de) * 1977-07-15 1979-01-25 Bayer Ag Penicilline, verfahren zu ihrer herstellung und ihre verwendung
JPS5446836A (en) * 1977-09-22 1979-04-13 Sangyo Kagaku Kenkyu Kyokai Antibacterial composition
US4610822A (en) * 1981-03-30 1986-09-09 American Cyanamid Company Process for preparing 6-[D(-)-α-(4-C1 -C4)-alkyl-2,3-dioxo-1-piperazinocarbonylamino)phenylacetamido]penicillanic acids
KR830001969B1 (ko) * 1981-10-06 1983-09-29 김영설 6―｛D―(―) α-(4―에틸-2. 3-디옥소-1 피페라지노카보닐아미노) 페닐(또는 하이드록시페닐)아세트아미도 페니실란산 및 그 염의 제조방법
JPS57118571A (en) * 1981-11-26 1982-07-23 Toyama Chem Co Ltd 1-ethyl-2,3-dioxopiperazine
YU43570B (en) * 1984-05-30 1989-08-31 Krka Process for preparation of derivatives of d()alpha-amino-benzile-penicilyns
PL145700B3 (en) * 1984-08-29 1988-10-31 Tarchominskie Zaklad Farma Method of obtaining 6-/d/-/alpha-/4-ethyl-2,3-dioxy-1-piperazinylocarbonyloamino/-phenylacetamido/-penicillate sodium salt
BG46664A1 (en) * 1985-08-16 1990-02-15 Druzhestven N Izsledovatelski Method for preparing of 6- /d (-)- alpha- (4- ethyl- 2, 3- dioxo- 1- piperazine carbonylamino)- phenylacetamido/- penicillanic acid
SI8711089A8 (en) * 1987-06-11 1996-08-31 Krka Tovarna Zdravil Process for preparation of 6-/d(-)-alpha-(4-ethyl-2,3-dioxo-1- piperazine-carboxyamido)-phenylacetamido/-penicillanic acid
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DD295852A5 (de) * 1988-07-18 1991-11-14 Arzneimittelwerk Dresden Gmbh,De Verfahren zur herstellung von acylureido-benzylpenicillinen und deren salzen
AU624421B2 (en) * 1988-10-05 1992-06-11 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
JP4749533B2 (ja) * 1999-09-30 2011-08-17 大塚化学株式会社 セファロスポリン結晶
JP4953501B2 (ja) * 1999-09-30 2012-06-13 大塚化学株式会社 ３−セフェム誘導体結晶の製造方法
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5123284A (en) 1974-08-13 1976-02-24 Toyama Chemical Co Ltd Shinkina penishirinruino seizoho
JPH0232082A (ja) 1988-07-21 1990-02-01 Maruko Seiyaku Kk ペニシリン誘導体の製造方法
US20030028016A1 (en) 2001-08-03 2003-02-06 Alberto Brandt Process for the preparation of the sodium salt of 6[D-(-)alpha-4-(ethyl-2,3-dioxo-1-piperazinocarbonylamino) phenylacetamido]penicillanic acid
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
JP2007246514A (ja) * 2006-02-14 2007-09-27 Toyama Chem Co Ltd ピペラシリンナトリウムの新規な結晶

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2128162A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011040386A1 (ja) * 2009-09-30 2011-04-07 富山化学工業株式会社 ピペラシリンナトリウム・１水和物の新規な結晶
JP2015531778A (ja) * 2012-09-14 2015-11-05 ベイジン シンティエンユー テクノロジー ディベロップメント シーオー エルティーディー ピペラシリンナトリウムとスルバクタムナトリウムの共晶及びその製造方法、並びに当該共晶を含む医薬組成物及びその応用

Also Published As

Publication number Publication date
US20100063273A1 (en) 2010-03-11
RU2009132516A (ru) 2011-03-10
IL200087A0 (en) 2010-04-15
BRPI0808375A2 (pt) 2014-07-01
CA2676803A1 (en) 2008-08-07
MX2009008124A (es) 2009-10-08
AU2008210929A1 (en) 2008-08-07
EP2128162A1 (en) 2009-12-02
JPWO2008093650A1 (ja) 2010-05-20
KR20090104855A (ko) 2009-10-06
JP5173842B2 (ja) 2013-04-03
CN101611040A (zh) 2009-12-23
EP2128162A4 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
WO2008093650A1 (ja) ピペラシリンナトリウムの新規な結晶
JO2650B1 (en) Solid product
WO2008144730A3 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
IL223770A0 (en) 6,7-dihydro-5h-benzo[7]annulene derivatives, methods of production thereof, pharmaceutical preparations containing them, and use thereof for the production of medicinal products
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
PE20120653A1 (es) Forma cristalina iv de la agomelatina y la composicion que la comprende
EP1728791A4 (en) COMPOSITIONS FOR SOLID PHARMACEUTICAL PREPARATION OF SOLIFENACIN OR BZW. A SALT OF IT
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
WO2009133100A3 (en) Ordered mesoporous silica material
IL192847A (en) The history of benzamide and the trower, a process for making them and their pharmaceutical preparations
WO2010089768A3 (en) Bortezumib containing pharmaceutical composition
WO2011085643A8 (zh) 吡啶并环衍生物
WO2008146016A3 (en) Cyclodextrins for administering fatty acids in tablets
WO2008006795A3 (en) Indole compounds
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
WO2007005633A3 (en) Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
MY151035A (en) ? crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
WO2008021235A3 (en) Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives
WO2009015981A3 (en) Treatment of pediatric tumors
WO2008116737A3 (de) Kapseln enthaltend pflanzenzubereitungen
WO2006041843A3 (en) Pharmaceutical dosage form comprising meloxicam
CN102757334B (zh) 苯丁酸钠ⅱ型晶体及其制备方法
RU2012111354A (ru) Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880003783.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704041

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008556092

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008210929

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200087

Country of ref document: IL

Ref document number: 2008704041

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2676803

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12524875

Country of ref document: US

Ref document number: 4951/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008124

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097016429

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008210929

Country of ref document: AU

Date of ref document: 20080129

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009132516

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0808375

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090727